Gilles Litman, former VP of Digital Well being at Sanofi, joins Remedee Labs to speed up world launch of breakthrough digital well being platform targeted on power ache administration


Prior to joining Remedee Labs, Gilles was Vice President of Digital Health at Sanofi, where he worked on technology platforms for diabetes and cardiovascular disease. Gilles is a graduate of ESSEC Paris and has more than 20 years of experience in the pharmaceutical industry. He has outstanding expertise in the areas of strategy, international development and corporate governance.

“Remedee Labs’ technological innovation and value proposition are unique and groundbreaking in how it is transforming the lives of chronic pain patients. I am excited to join Remedee Labs to accelerate product offerings and drive international expansion and business development. We have big goals at Remedee Labs, including our main focus on bringing our services to as many people with chronic pain as possible. “
Gilles Litman, Chief Business Officer of Remedee Labs

Changing the lives of patients with chronic pain through an endorphin stimulator and a digital service platform

Remedee Labs has developed a breakthrough, unique non-invasive endorphin stimulation technology to improve the quality of life for patients with chronic pain.

The Remedee platform enables a comprehensive and personalized experience through multidisciplinary care designed for both patients and clinicians. The platform enables remote support from care teams, trainers, practitioners and more and includes personalized digital services that are available around the clock.

“Drugs alone are often not enough to relieve chronic pain patients. Holistic care and the combination of multiple approaches are essential. The Remedee Platform addresses this need and enables improvements in the patient’s treatment pathway.”
Prof. Prof. Alain Serrie, Head of the Department of Pain and Palliative Medicine at AP-HP and Founding Chairman of Douleur Sans Frontière.

Useful for diseases without satisfactory treatment such as fibromyalgia and endometriosis, but also for migraines and osteoarthritis

Fibromyalgia is a debilitating chronic condition that affects many aspects of healthy living and quality of life. Treatment options are inconsistent, can be expensive, and often have a variety of undesirable side effects.

Technology developed by Remedee Labs to reduce stress and improve sleep has been shown to dramatically improve the quality of life for patients with fibromyalgia. In light of these promising results, Remedee Labs is launching a multicenter study on fibromyalgia and developing the first personalized pathway for this condition.

“We will develop this platform with the help of patients who suffer from fibromyalgia. In addition to a clinical study that we are starting under this condition with our personal endorphin stimulator – the only technology of its kind in the world.”
David Crouzier, Co-Founder and CEO of Remedee Labs

In addition, Remedee Labs is expanding its range of services to treat other chronic pain conditions and has started several clinical studies in endometriosis, osteoarthritis, migraines and cancer pain. Early data indicate potent effectiveness in reducing pain in a variety of pathologies from digitally stimulated endorphin pathways.

Global development potential

1.5 billion people worldwide suffer from chronic pain, 50% of which have not found satisfactory treatment1 and most say it affects their daily personal, social and professional life

“Gilles comes to us at an important time in the company’s history. With his expertise, we can accelerate the development of our service platform for patients with chronic pain and begin our international expansion.”
Jacques Husser, Co-Founder & Exec Chairman, Remedee Labs

Remedee Labs has raised 11 million euros to date. Further announcements are expected shortly to support the company’s ambitions.

Endorphin stimulation with millimeter waves as an alternative to the treatment of chronic pain

Remedee Labs designed and developed the first endorphin stimulation solution that transforms the management of chronic pain.

This technology is the result of many years of scientific research and strong partnerships (CEA-Leti, ST Microelectronics) and is based on the patented MEET module (Microelectronic Endorphin Trigger), the first miniature module that emits millimeter waves. Embedded in a bracelet and delivered on the inside of the wrist, this module delivers a high frequency electronic signal that precisely stimulates the subcutaneous receptors (0.5 mm inside the skin).

In response to this painless nerve stimulation, the brain releases intracerebral endorphins, which quickly relieve pain and also create a sense of well-being.

About Remedee Labs

1.5 billion people worldwide suffer from chronic pain and over half of them are not satisfied with their care. Remedee Labs would like to give these patients a new life.

Based on 10 years of preclinical and clinical research, Remedee Labs created the first endorphin stimulator for personal use. Building on the experience of its clinical partners, the company is now using its unique technology to work with doctors to offer the first patient-centered digital service platform for the treatment of chronic pain. Remedee Labs is initially focused on helping patients with fibromyalgia and plans to expand the platform offering to other chronic pain conditions in the future.

Remedee Labs was founded in 2016 and announced in 2019 that it had increased 11 million euros from investors such as HCVC, Habert Dassault Finance, Partech, Supernova Invest and C4 Venture.


Remedee Labs, Quentin Richard, +33 (0) 7 67 17 01 91, [email protected]
Agence PRPA, Damien Maillard, [email protected]

Photo –
Logo –

SOURCE Remedee Labs